| Abstrakt: |
Background:The role of osteoprotegerin (OPG) as a marker of cardiovascular disease (CVD) in Type 2 diabetes (T2DM) is not well established. Moreover, the relationship between OPG, osteoporosis, and vertebral fractures in T2DM remains to be elucidated. Aim:To determine the role of serum OPG in the prediction of CVD and bone disease in T2DM males. Subjects and methods:Cross-sectional study with 68 males, 43 with T2DM and 25 subjects without diabetes. We measured: serum OPG by inmunoassay, the presence of CVD (coronary heart disease, cerebrovascular and peripheral artery disease), surrogate markers of CVD [intima-media thickness (IMT) and aortic calcification] and bone disease (bone mineral density and prevalent vertebral fractures). Results:OPG serum levels (in pmol/l) were significantly higher in T2DM males with abnormal IMT (5. 12±1. 59 vs 3. 76±1. 98), carotid plaque (5. 46±1. 67 vs 4. 20±1. 81), aortic calcification (5. 91±1. 39 vs 4. 07±1. 76), hypertension (5. 11 ±1. 86 vs 3. 81 ±1. 47), and peripheral artery disease (6. 24±1. 64 vs 4. 21 ±1. 63, p<0. 05 for all comparisons). In the logistic regression analysis (after adjustment for age and main cardiovascular risk factors), serum OPG (per 1 pmol/l increase in OPG) was associated with increased risk of abnormal IMT [odds ratio (OR) 1. 84, confidence interval (CI) 1. 21–2. 79, p=0. 004), carotid plaque (OR 1. 71, CI 1. 13–2. 58, p=0. 012), aortic calcification (OR 2. 21, CI 1. 27–3. 84, p=0. 05) and peripheral artery disease (OR 4. 02, CI 1. 65–9. 8 p=0. 002). However, OPG were not related to bone mass or vertebral fractures. Conclusions:Our results suggest that in T2DM males OPG serum concentrations constitute a marker of CVD, but not a marker of bone disease. |
Full text from SpringerLink